129 related articles for article (PubMed ID: 33091717)
1. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Rauschenbach L; Wieland A; Reinartz R; Kebir S; Till A; Darkwah Oppong M; Dobersalske C; Ullrich V; Ahmad A; Jabbarli R; Pierscianek D; Fröhlich H; Simon M; Brüstle O; Sure U; Glas M; Scheffler B
Eur J Cancer; 2020 Nov; 140():130-139. PubMed ID: 33091717
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Azzalin A; Nato G; Parmigiani E; Garello F; Buffo A; Magrassi L
Neoplasia; 2017 Apr; 19(4):364-373. PubMed ID: 28319810
[TBL] [Abstract][Full Text] [Related]
3. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
4. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
[TBL] [Abstract][Full Text] [Related]
5. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
[TBL] [Abstract][Full Text] [Related]
6. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D;
AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943
[TBL] [Abstract][Full Text] [Related]
9. Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and
Swami D; Mudaliar P; Bichu YS; Kumar Sahu V; Devarajan S; Basu S; Aich J
J Biomol Struct Dyn; 2023; 41(12):5802-5816. PubMed ID: 35818867
[TBL] [Abstract][Full Text] [Related]
10. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
12. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
13. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL
Sci Rep; 2019 Feb; 9(1):2905. PubMed ID: 30814573
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
[TBL] [Abstract][Full Text] [Related]
15. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
16. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
17. Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Cooper E; Choi PJ; Schweder P; Mee E; Turner C; Faull R; Denny WA; Dragunow M; I-H Park T; Jose J
Bioorg Med Chem Lett; 2021 Oct; 50():128336. PubMed ID: 34438012
[TBL] [Abstract][Full Text] [Related]
18. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
[TBL] [Abstract][Full Text] [Related]
20. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
